Vulvo Vaginal Atrophy
Conditions
Keywords
Vulvo vaginal atrophy, Femarelle
Brief summary
Based on previous data published on the SERM properties of Femarelle, the investigators hypothesized that Femarelle could be a potential treatment for Vulvo-vaginal atrophy(VVA) symptoms. The current study was a pilot study to examine the effect of Femarelle® on VVA symptoms in symptomatic post-menopausal women.
Detailed description
Post-menopausal women aged 54-77, with vaginal atrophy (\< 5% superficial cells on cervical cytology) with at least one moderate-to-severe VVA symptom (dryness, irritation, soreness, dysuria, dyspareunia, or bleeding with coitus), will be recruited for a 12-week open-label pilot study. The study protocol was approved by Schulman Associates IRB.Femarelle will be given twice daily and subjective symptoms as well as objective measures like inspection and vaginal pH will be measured.
Interventions
DIETARY_SUPPLEMENTFemarelle
Twice daily oral treatment with Femarelle
Sponsors
Se-cure Pharmaceuticals Ltd.
Dr. Lila Nachtigall Rapid Medical Research, New York
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy post menopausal women between the ages of 40-85+yrs who complain of vaginal dryness with at least three urogenital symptoms from the following: vaginal dryness, vaginal irritation, vaginal soreness, dysuria, dyspareunia, bleeding with coitus & one of these symptoms must be moderate to severe as determined by patient, Moderate: discomforting and aware of it with activities. Severe: discomforting enough to interfere with activities Activities include sitting, walking, running, urinating, as well as sexual activity * BMI 18-34 (inclusive). * Patients having a LMP at least one year ago, either natural or surgical. * Patients with a normal mammogram within 9 months prior to enrollment. * Patients able to adhere to the visit schedule and protocol requirements and be available to complete the study. * Patients who provide written informed consent to participate in the study. * FSH \> 40 mIU/m. * Estradiol \< 20 pg/ml. * Vaginal PH \> 5. * \< 5% superficial cells as assessed by vaginal cytology. * Normal pelvic and breast exams by investigator.
Exclusion criteria
Patients using HRT (cannot have used for past 3 months). * Patients consuming over the last three months high soy diet or any foods or other compounds that are sold as remedies for the post menopausal symptoms. * Any history of significant cancer or pre-cancer, neurological, renal, cardiovascular, respiratory (e.g. asthma, COPD), hypercoagulability, hematopoietic disease, immune deficiency or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medications. * Patients with any clinically significant abnormality upon examination at screening visit. * Patients with a known history of drug or alcohol abuse. * Known hypersensitivity and/or allergy to soy or flax. * Participation in another clinical trial within the past 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| improvement in VVA symptoms | 12 weeks | Subjective and objective measures of VVA |
Countries
United States
Outcome results
None listed